Lv51
1094 积分 2021-12-13 加入
Safety considerations for cereblon-recruiting targeted protein degraders
10小时前
已完结
Abstract PS7-03: A first-in-human phase 1a/b trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant, allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors: Results from the PIKASSO-01 study
15天前
已关闭
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
23天前
已完结
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression
1个月前
已完结
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
1个月前
已完结
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
1个月前
已完结
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
1个月前
已完结
Amylin analogues as a novel perspective in anti‐obesity therapy
1个月前
已完结
The story of amylin: from physiology to therapy
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
皖公网安备34019202002308
